[
    [
        {
            "time": "",
            "original_text": "医药生物行业点评报告：《“十四五”全民医疗保障规划》发布 进一步推进医疗保障高质量发展",
            "features": {
                "keywords": [
                    "医药生物",
                    "十四五",
                    "全民医疗保障",
                    "高质量发展"
                ],
                "sentiment_score": 0.9,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "医药生物行业点评报告：《“十四五”全民医疗保障规划》发布 进一步推进医疗保障高质量发展",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 5,
                "Market_Scope": 10,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "注册制新股纵览：可孚医疗：国内领先的综合性家用医疗器械企业",
            "features": {
                "keywords": [
                    "注册制",
                    "新股",
                    "可孚医疗",
                    "家用医疗器械"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "医疗器械"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "注册制新股纵览：可孚医疗：国内领先的综合性家用医疗器械企业",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "大参林医药集团股份有限公司 2021年第三季度报告",
            "features": {
                "keywords": [
                    "大参林",
                    "医药集团",
                    "第三季度报告",
                    "2021"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "大参林医药集团股份有限公司 2021年第三季度报告",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]